Clinically relevant of Cytochrome P450 Family enzymes for drug-drug interaction in anticancer therapy

WCRJ 2015; 2 (2): e524

Topic: Pharmacogenomics Category: Review

Rainone A.

GORI “Gruppo Oncologico Ricercatori Italiani” Onlus, Pordenone, Italy
rainoneaniello@gmail.com Close

, De Lucia D.

Department of Neurology, Azienda Policlinico Second University of Naples (SUN), Naples, Italy Close

, Morelli C. D.

GORI “Gruppo Oncologico Ricercatori Italiani” Onlus, Pordenone, Italy Close

, Valente D.

Research Center CETAC, Caserta, Italy Close

, Catapano O.

Italian Association of Pharmacogenomics and Molecular Diagnostics, Caserta, Italy Close

, Caraglia M.

Department of Biochemical, Biophysical and Pathology, Second University of Naples (SUN), Naples, Italy Close

Abstract

In the oncology field, the knowledge of secondary mechanisms for drug metabolism allow physicians to improve the efficacy of cancer therapy.

This review provides an overview on the commonly occurring, functionally and/or clinically relevant Cytochrome P450 (CYP) superfamily. Particular highlight were attempt on genetic variations in the CYP2D6 gene and the pharmacokinetics and/or response of drug-based chemotherapy. In addition, current genetic polymorphisms responsible of variability in drug-drug interaction between anticancer drugs and antidepressant are discussed.

Further, effective re-evaluation of drug design based on CYP enzymes profile may eventually be personalized and individualized to the patient for maximum efficacy of the therapies.

Free PDF Download

To cite this article